vs
P10, Inc.（PX）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
P10, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.2倍（$81.0M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 11.7%，领先372.4%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -4.7%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 10.7%）
P10, Inc.是一家全球另类资产管理公司，提供涵盖私募股权、私募信贷、实物资产、风险投资的多元化投资解决方案，主要服务北美、欧洲、亚太市场的养老基金、捐赠基金、基金会及高净值个人等客户群体。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
PX vs RIGL — 直观对比
营收规模更大
PX
是对方的1.2倍
$69.8M
营收增速更快
RIGL
高出25.9%
-4.7%
净利率更高
RIGL
高出372.4%
11.7%
两年增速更快
RIGL
近两年复合增速
10.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $81.0M | $69.8M |
| 净利润 | $9.5M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 31.9% | 33.2% |
| 净利率 | 11.7% | 384.0% |
| 营收同比 | -4.7% | 21.2% |
| 净利润同比 | 79.0% | 1769.2% |
| 每股收益（稀释后） | $0.08 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PXRIGL
| Q4 25 | $81.0M | $69.8M | ||
| Q3 25 | $75.9M | $69.5M | ||
| Q2 25 | $72.7M | $101.7M | ||
| Q1 25 | $67.7M | $53.3M | ||
| Q4 24 | $85.0M | $57.6M | ||
| Q3 24 | $74.2M | $55.3M | ||
| Q2 24 | $71.1M | $36.8M | ||
| Q1 24 | $66.1M | $29.5M |
净利润PXRIGL
| Q4 25 | $9.5M | $268.1M | ||
| Q3 25 | $2.1M | $27.9M | ||
| Q2 25 | $3.4M | $59.6M | ||
| Q1 25 | $4.5M | $11.4M | ||
| Q4 24 | $5.3M | $14.3M | ||
| Q3 24 | $1.4M | $12.4M | ||
| Q2 24 | $7.0M | $-1.0M | ||
| Q1 24 | $5.0M | $-8.2M |
毛利率PXRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率PXRIGL
| Q4 25 | 31.9% | 33.2% | ||
| Q3 25 | 14.1% | 40.9% | ||
| Q2 25 | 24.4% | 60.1% | ||
| Q1 25 | 16.6% | 23.9% | ||
| Q4 24 | 26.9% | 28.9% | ||
| Q3 24 | 11.9% | 25.4% | ||
| Q2 24 | 23.7% | 1.2% | ||
| Q1 24 | 18.3% | -23.6% |
净利率PXRIGL
| Q4 25 | 11.7% | 384.0% | ||
| Q3 25 | 2.8% | 40.2% | ||
| Q2 25 | 4.7% | 58.6% | ||
| Q1 25 | 6.7% | 21.5% | ||
| Q4 24 | 6.2% | 24.9% | ||
| Q3 24 | 1.9% | 22.5% | ||
| Q2 24 | 9.8% | -2.8% | ||
| Q1 24 | 7.6% | -27.9% |
每股收益（稀释后）PXRIGL
| Q4 25 | $0.08 | $14.11 | ||
| Q3 25 | $0.02 | $1.46 | ||
| Q2 25 | $0.03 | $3.28 | ||
| Q1 25 | $0.04 | $0.63 | ||
| Q4 24 | $0.05 | $0.82 | ||
| Q3 24 | $0.01 | $0.70 | ||
| Q2 24 | $0.06 | $-0.06 | ||
| Q1 24 | $0.04 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $28.2M | $155.0M |
| 总债务越低越好 | $373.2M | $52.5M |
| 股东权益账面价值 | $403.5M | $391.5M |
| 总资产 | $928.3M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.93× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资PXRIGL
| Q4 25 | $28.2M | $155.0M | ||
| Q3 25 | $40.0M | $137.1M | ||
| Q2 25 | $33.4M | $108.4M | ||
| Q1 25 | $74.4M | $77.1M | ||
| Q4 24 | $67.5M | $77.3M | ||
| Q3 24 | $61.5M | $61.1M | ||
| Q2 24 | $31.2M | $49.1M | ||
| Q1 24 | $29.0M | $49.5M |
总债务PXRIGL
| Q4 25 | $373.2M | $52.5M | ||
| Q3 25 | $393.4M | $60.0M | ||
| Q2 25 | $373.0M | $60.0M | ||
| Q1 25 | $357.2M | $60.0M | ||
| Q4 24 | $319.8M | $60.0M | ||
| Q3 24 | $319.4M | $60.0M | ||
| Q2 24 | $300.6M | $60.0M | ||
| Q1 24 | $314.0M | $60.0M |
股东权益PXRIGL
| Q4 25 | $403.5M | $391.5M | ||
| Q3 25 | $396.8M | $117.6M | ||
| Q2 25 | $388.9M | $81.9M | ||
| Q1 25 | $374.3M | $18.6M | ||
| Q4 24 | $386.9M | $3.3M | ||
| Q3 24 | $394.1M | $-14.6M | ||
| Q2 24 | $396.9M | $-29.9M | ||
| Q1 24 | $400.1M | $-31.7M |
总资产PXRIGL
| Q4 25 | $928.3M | $513.6M | ||
| Q3 25 | $936.0M | $242.5M | ||
| Q2 25 | $932.2M | $206.7M | ||
| Q1 25 | $877.4M | $176.0M | ||
| Q4 24 | $869.3M | $164.0M | ||
| Q3 24 | $857.0M | $139.4M | ||
| Q2 24 | $823.2M | $128.4M | ||
| Q1 24 | $832.8M | $126.5M |
负债/权益比PXRIGL
| Q4 25 | 0.93× | 0.13× | ||
| Q3 25 | 0.99× | 0.51× | ||
| Q2 25 | 0.96× | 0.73× | ||
| Q1 25 | 0.95× | 3.23× | ||
| Q4 24 | 0.83× | 18.25× | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.78× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $18.1M | — |
| 自由现金流率自由现金流/营收 | 22.3% | — |
| 资本支出强度资本支出/营收 | 6.0% | — |
| 现金转化率经营现金流/净利润 | 2.43× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $14.1M | — |
8季度趋势，按日历期对齐
经营现金流PXRIGL
| Q4 25 | $23.0M | $22.0M | ||
| Q3 25 | $-8.6M | $24.0M | ||
| Q2 25 | $13.4M | $30.5M | ||
| Q1 25 | $-4.7M | $-893.0K | ||
| Q4 24 | $101.0M | $14.5M | ||
| Q3 24 | $27.5M | $21.7M | ||
| Q2 24 | $34.8M | $302.0K | ||
| Q1 24 | $11.0M | $-5.0M |
自由现金流PXRIGL
| Q4 25 | $18.1M | — | ||
| Q3 25 | $-9.5M | — | ||
| Q2 25 | $11.6M | — | ||
| Q1 25 | $-6.0M | — | ||
| Q4 24 | $96.6M | — | ||
| Q3 24 | $25.2M | — | ||
| Q2 24 | $33.9M | — | ||
| Q1 24 | $10.7M | — |
自由现金流率PXRIGL
| Q4 25 | 22.3% | — | ||
| Q3 25 | -12.6% | — | ||
| Q2 25 | 15.9% | — | ||
| Q1 25 | -8.9% | — | ||
| Q4 24 | 113.6% | — | ||
| Q3 24 | 34.0% | — | ||
| Q2 24 | 47.7% | — | ||
| Q1 24 | 16.2% | — |
资本支出强度PXRIGL
| Q4 25 | 6.0% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.2% | — | ||
| Q3 24 | 3.0% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 0.4% | — |
现金转化率PXRIGL
| Q4 25 | 2.43× | 0.08× | ||
| Q3 25 | -4.01× | 0.86× | ||
| Q2 25 | 3.96× | 0.51× | ||
| Q1 25 | -1.05× | -0.08× | ||
| Q4 24 | 19.12× | 1.01× | ||
| Q3 24 | 19.54× | 1.75× | ||
| Q2 24 | 4.98× | — | ||
| Q1 24 | 2.18× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PX
| Management Fees | $78.1M | 96% |
| Advisory Fees | $1.8M | 2% |
RIGL
暂无分部数据
